52/100
Opportunity
Commercial fit6/25
Clinical timing18/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency5/5
New phase 3 trial NCT06119581 posted by Eli Lilly and Company: "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).
Why nowClinicalTrials.gov record updated today.
ConfidenceHigh · 87%